

## From Cell Line to Clinic 4 Months Sooner with mAb Accelerator

The mAb Accelerator is designed to accelerate your success by



### Early Investment

We commit resources upfront, helping you overcome early financial and operational barriers.



### Risk Sharing

We share early technical and operational risks so you can advance your programs before certainty sets in.



### Flexible Commercial Models

We offer stage-based, biotech-aligned payment structures that minimize upfront costs and enable you to progress without straining your capital.

# Eliminating Early-Stage Bottlenecks in Biologics Development

The mAb Accelerator program is created in response to a fundamental disconnect we repeatedly saw in early and mid-stage biologics development i.e. innovation is moving faster than the systems supporting it. Across biotech and biopharma, we observed strong science being delayed, not because of technical limitations but because of organizational uncertainty, funding cycles, governance approvals, partner alignment, and portfolio decisions. These delays often occur before the most value-creating work cell line development could even begin.

To address these challenges, Syngene introduces the mAb Accelerator program, which initiates cell line development immediately, so your molecule progresses while you secure approvals and funding. The program then advances your asset from Gene-to-GMP typically in 9 months (with DP ~10 months), but expedited timelines are available, through an integrated end-to-end CDMO footprint across the U.S. and India. It is powered by SynWeave™ high-titer CLD platform (7–12 g/L), FDA/EMA-approved sites, and state-of-the-art 2 KL and 4 KL single-use bioreactors, totaling 50 KL of global single-use capacity.

## 3 Core Problems mAb Accelerator Solves for Biopharma Companies

mAb Accelerator is designed to help you accelerate innovation by providing the lowest risk path to IND. It democratizes access to proven transposase-based cell line development, ensuring that scientific progress is driven by data and informed decisions rather than capital constraints.

Core Problems	Syngene Solution
<p><b>A) Time Lost to Inaction</b></p> <ul style="list-style-type: none"> <li>Cell Line Development (CLD) is often delayed while approvals, funding, or partnerships are finalized</li> <li>These months create zero asset value, even though the program clock keeps ticking</li> </ul>	<p><b>A) Head Start That Actually Changes Outcomes</b></p> <p>By starting CLD immediately, customers gain up to a 4 month head start that translates into</p> <ul style="list-style-type: none"> <li>Earlier access to strong IND package</li> <li>Earlier clinical entry</li> <li>Better leverage in partnering or fundraising discussions</li> </ul>
<p><b>B) Concentrated Early Stage Risk</b></p> <ul style="list-style-type: none"> <li>The highest technical and financial risk exists at the very beginning (CLD can represent 10-30% of pre-IND spending)</li> <li>Traditional CDMO models shift this risk almost entirely onto the customer, with full upfront commitments</li> </ul>	<p><b>B) Risk Sharing by Design</b></p> <p>This is not acceleration through speed alone; it is acceleration through shared conviction. We move forward before certainty sets in, reducing timeline risk and increasing asset readiness.</p> <ul style="list-style-type: none"> <li>Syngene absorbs early technical and operational risk</li> <li>Customers gain progress without front loading exposure</li> <li>The program signals confidence in the molecule, not just capacity availability</li> </ul>
<p><b>C) Runway Pressure</b></p> <ul style="list-style-type: none"> <li>Biotechs in particular face capital constraints that force them to choose between advancing science and preserving cash</li> <li>This trade off slows progress and weakens negotiating leverage with investors or partners</li> </ul>	<p><b>C) Capital Sensitive, Flexible Commercial Models</b></p> <p>The program is structured around the biotech economics so that customers can preserve runway while still making real scientific progress.</p> <ul style="list-style-type: none"> <li>Flexible, stage aligned payment structures</li> <li>Spend aligned to meaningful development milestones</li> <li>Reduced upfront financial pressure during the highest risk phase</li> </ul>

# Distinctive Features of the mAb Accelerator Program

## Molecule First.



### Head-Start Model

Rapid contracting through simplified templates, enabling Cell Line Development (CLD) to begin within 4 weeks of signature, saving up to ~4 months while approvals or funding progress in parallel.



### Risk-Sharing Approach

Syngene commits capacity, resources, and scientific expertise upfront, sharing early technical and operational risk alongside the customer.



### Flexible Commercial Models

Designed around biotech economics to preserve runway, with milestone-based spend, shared success models, and reduced upfront financial exposure during early development.

## Integrated Programs. Accelerated Timelines.



### Accelerated Time to Clinic

Seamless progression from Gene to GMP in ~10 months, enabled by integrated drug substance (DS) and drug product (DP) capabilities.



### Proven CLD Platform

Powered by SynWeave™, delivering 7–12 g/L titers with robust scalability.



### End-to-End ADC Continuum

Integrated mAb development and GMP bioconjugation under one roof, reducing supply chain complexity and timelines.



### High-Throughput Fill-Finish

Clinical and commercial DP capabilities supporting up to 1 million vials per day.

## Scale. Compliance. Reliability.



### Global, Integrated Footprint

U.S. and India manufacturing network with 50 KL single-use bioreactor (SUB) capacity, including flexible scale-up using 2 KL and 4 KL SUBs.



### Demonstrated Execution Excellence

150+ biologics programs | 25+ INDs | 250+ GMP batches delivered.



### Strong Regulatory Pedigree

Multiple FDA and EMA-approved sites, supporting global clinical and commercial pathways.



### Sustainable Operations


Manufacturing powered by >80% green energy, supporting responsible and resilient supply chains.

# A Partnership That Takes Your Molecule All the Way

Our Gene to GMP program is more than a service, it's a strategic alliance that aligns our capabilities with your goals. By supporting your cell line development program, we're not just reducing your financial risk, we're demonstrating our confidence in your molecule's potential. Whether you're a biotech startup or a global pharma leader, Syngene is committed to being your partner from bench to bedside.

Let's take the first step together, because your success is our starting point.

## Gene to GMP in 9 Months



Scan the QR code to learn more

### About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's 6000+ scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb, as well as 2.2 million sq. ft. of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.

For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com) or write to us at [bdc@syngeneintl.com](mailto:bdc@syngeneintl.com)

© 2026 Syngene International Limited, All Rights Reserved.

Stay Connected

